HLB Therapeutics Co.,Ltd. Statistics

Total Valuation

HLB Therapeutics Co.,Ltd. has a market cap or net worth of KRW 980.38 billion. The enterprise value is 991.95 billion.

Market Cap	980.38B
Enterprise Value	991.95B

Important Dates

The next estimated earnings date is Friday, February 21, 2025.

Earnings Date	Feb 21, 2025
Ex-Dividend Date	n/a

Share Statistics

HLB Therapeutics Co.,Ltd. has 83.79 million shares outstanding. The number of shares has increased by 3.82% in one year.

Current Share Class	n/a
Shares Outstanding	83.79M
Shares Change (YoY)	+3.82%
Shares Change (QoQ)	-1.11%
Owned by Insiders (%)	0.30%
Owned by Institutions (%)	5.41%
Float	73.05M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	16.19
PB Ratio	6.68
P/TBV Ratio	7.19
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-34.38
EV / Sales	17.94
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-246.40

Financial Position

The company has a current ratio of 3.40, with a Debt / Equity ratio of 0.12.

Current Ratio	3.40
Quick Ratio	2.26
Debt / Equity	0.12
Debt / EBITDA	n/a
Debt / FCF	-4.86
Interest Coverage	-5.73

Financial Efficiency

Return on equity (ROE) is -16.57% and return on invested capital (ROIC) is -3.30%.

Return on Equity (ROE)	-16.57%
Return on Assets (ROA)	-3.05%
Return on Capital (ROIC)	-3.30%
Revenue Per Employee	594.60M
Profits Per Employee	-310.20M
Employee Count	93
Asset Turnover	0.27
Inventory Turnover	6.82

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +208.25% in the last 52 weeks. The beta is -0.02, so HLB Therapeutics Co.,Ltd.'s price volatility has been lower than the market average.

Beta (5Y)	-0.02
52-Week Price Change	+208.25%
50-Day Moving Average	10,663.66
200-Day Moving Average	9,302.25
Relative Strength Index (RSI)	52.09
Average Volume (20 Days)	1,059,050

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HLB Therapeutics Co.,Ltd. had revenue of KRW 55.30 billion and -28.85 billion in losses. Loss per share was -376.93.

Revenue	55.30B
Gross Profit	7.77B
Operating Income	-10.16B
Pretax Income	-28.69B
Net Income	-28.85B
EBITDA	-1.91B
EBIT	-10.16B
Loss Per Share	-376.93

Full Income Statement

Balance Sheet

The company has 29.95 billion in cash and 19.57 billion in debt, giving a net cash position of 10.38 billion or 123.86 per share.

Cash & Cash Equivalents	29.95B
Total Debt	19.57B
Net Cash	10.38B
Net Cash Per Share	123.86
Equity (Book Value)	168.62B
Book Value Per Share	1,750.46
Working Capital	42.01B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -3.34 billion and capital expenditures -686.70 million, giving a free cash flow of -4.03 billion.

Operating Cash Flow	-3.34B
Capital Expenditures	-686.70M
Free Cash Flow	-4.03B
FCF Per Share	-48.04

Full Cash Flow Statement

Margins

Gross margin is 14.06%, with operating and profit margins of -18.36% and -52.17%.

Gross Margin	14.06%
Operating Margin	-18.36%
Pretax Margin	-51.88%
Profit Margin	-52.17%
EBITDA Margin	-3.46%
EBIT Margin	-18.36%
FCF Margin	n/a

Dividends & Yields

HLB Therapeutics Co.,Ltd. does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.82%
Shareholder Yield	-3.82%
Earnings Yield	-3.22%
FCF Yield	-0.41%

Stock Splits

The last stock split was on January 14, 2025. It was a forward split with a ratio of 1.05.

Last Split Date	Jan 14, 2025
Split Type	Forward
Split Ratio	1.05

Scores

HLB Therapeutics Co.,Ltd. has an Altman Z-Score of 9.81.

Altman Z-Score	9.81
Piotroski F-Score	n/a